Additional Patent Claims Awarded to Ventris Medical’s Bone Graft Containment System

Ventris Medical has secured additional patent coverage for its Backpack bone graft containment system, underscoring the product’s design and functional advantages that help enhance spinal fusion procedures.

The expanded patent protection reflects the ongoing innovation in the Backpack bone graft containment system, a product the company claims is a significant step forward in orthopedic surgery since it offers a specialized solution for containing bone graft material during complex procedures. The additional patent coverage strengthens Ventris Medical’s intellectual property portfolio, demonstrating the distinctive and proprietary nature of its technology in a competitive medical device landscape, executives claim.

The Backpack bone graft containment system provides surgeons with enhanced control and efficiency in managing bone grafts, which is critical for successful patient outcomes. This strategic patent rights expansion ensures that Ventris Medical’s contributions to surgical methodology and device design are protected, thus enabling the company to further invest in research and development for future advancements.

“We’re thrilled to receive this Notice of Allowance,” Ventris Medical CEO Russell Cook stated. “This patent validates years of focused R&D and represents a meaningful step forward in solving one of the biggest challenges in bone grafting—maintaining the graft exactly where the surgeon places it. Our containment system should improve outcomes and give surgeons greater confidence in both routine and complex procedures.”

The allowed patent protects a bioresorbable casing that securely holds bone graft material at the surgical site to prevent migration while allowing nutrient flow, vascular ingrowth, and new bone formation. The system is engineered to degrade naturally as the graft integrates with the patient’s own bone, allowing for predictable outcomes.

Ventris offers various allograft, synthetic, and bioactive products for soft and hard tissue applications. The Newport Beach, Calif.-based company designs, develops, and markets best-in-class products for optimal surgical outcomes. Its human allografts are regulated by the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER), which manages human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Ventris Allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act.